Centhaquine Explained
| Drug Name: | Centhaquine |
| Tradename: | Lyfaquin |
| Legal Status: | Rx-only |
| Synonyms: | Centhaquin; PMZ-2010; Compound-7173 |
| Cas Number: | 57961-90-7 |
| Pubchem: | 162163 |
| Unii: | QD4VI0J9T5 |
| Drugbank: | DB16122 |
| Chembl: | 4594437 |
| Iupac Name: | 2-[2-[4-(3-Methylphenyl)piperazin-1-yl]ethyl]quinoline |
| C: | 22 |
| H: | 25 |
| N: | 3 |
| Smiles: | CC1=CC(=CC=C1)N2CCN(CC2)CCC3=NC4=CC=CC=C4C=C3 |
| Stdinchi: | InChI=1S/C22H25N3/c1-18-5-4-7-21(17-18)25-15-13-24(14-16-25)12-11-20-10-9-19-6-2-3-8-22(19)23-20/h2-10,17H,11-16H2,1H3 |
| Stdinchikey: | UJNWGFBJUHIJKK-UHFFFAOYSA-N |
Centhaquine (brand name Lyfaquin) is a cardiovascular drug.[1] In India, it is approved for the treatment of hypovolemic shock.[2]
Centhaquine is a vasopressor that activates α2A- and α2B-adrenoreceptors.[3] It increases venous return and improves tissue perfusion.
Notes and References
- Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, Dhibar DP, Prabhu M, Haveri S, Agarwal R, Lavhale MS . Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial . Advances in Therapy . 38 . 6 . 3223–3265 . June 2021 . 33970455 . 10.1007/s12325-021-01760-4 . 8189997 .
- Marketing authorization received for Lyfaquin (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency . May 14, 2020 . April 25, 2024 . August 9, 2022 . https://web.archive.org/web/20220809180311/https://www.prnewswire.com/news-releases/marketing-authorization-received-for-lyfaquin-centhaquine-to-treat-patients-with-hypovolemic-shock-from-indian-regulatory-agency-301059610.html . live .
- Chalkias A, Pais G, Gulati A . Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species . International Journal of Molecular Sciences . 25 . 6 . 3494 . March 2024 . 38542464 . 10.3390/ijms25063494 . free . 10970680 .
